PE20200756A1 - Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica - Google Patents
Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologicaInfo
- Publication number
- PE20200756A1 PE20200756A1 PE2020000257A PE2020000257A PE20200756A1 PE 20200756 A1 PE20200756 A1 PE 20200756A1 PE 2020000257 A PE2020000257 A PE 2020000257A PE 2020000257 A PE2020000257 A PE 2020000257A PE 20200756 A1 PE20200756 A1 PE 20200756A1
- Authority
- PE
- Peru
- Prior art keywords
- mglur4
- alkyl
- enhancers
- alosteric
- compositions
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101150025480 Grm4 gene Proteins 0.000 title 1
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200756A1 true PE20200756A1 (es) | 2020-07-27 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000257A PE20200756A1 (es) | 2017-08-16 | 2018-08-16 | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11427573B2 (https=) |
| EP (1) | EP3668865A1 (https=) |
| JP (1) | JP7253832B2 (https=) |
| KR (1) | KR102687118B1 (https=) |
| CN (1) | CN111225913B (https=) |
| AU (1) | AU2018317403B2 (https=) |
| BR (1) | BR112020003292A2 (https=) |
| CA (1) | CA3072493A1 (https=) |
| CL (1) | CL2020000360A1 (https=) |
| CO (1) | CO2020002576A2 (https=) |
| EA (1) | EA202090467A1 (https=) |
| IL (1) | IL272575B2 (https=) |
| PE (1) | PE20200756A1 (https=) |
| SG (1) | SG11202001264UA (https=) |
| UA (1) | UA128084C2 (https=) |
| WO (1) | WO2019036534A1 (https=) |
| ZA (1) | ZA202001321B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2019006157A1 (en) | 2017-06-28 | 2019-01-03 | Vanderbilt University | Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| JP2025540259A (ja) * | 2022-12-08 | 2025-12-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| MX2009006401A (es) | 2006-12-20 | 2009-06-23 | Nerviano Medical Sciences Srl | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| AU2010208176A1 (en) | 2009-01-28 | 2011-09-15 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2456310A4 (en) | 2009-07-23 | 2013-01-23 | Univ Vanderbilt | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS |
| RU2012114770A (ru) | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| JP2013508413A (ja) | 2009-10-22 | 2013-03-07 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| KR20120115252A (ko) | 2009-11-06 | 2012-10-17 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법 |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2533639A4 (en) | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| MX2012009377A (es) | 2010-02-11 | 2012-09-12 | Univ Vanderbilt | Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica. |
| EP2568809A4 (en) | 2010-05-12 | 2013-11-06 | Univ Vanderbilt | HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016115282A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
-
2018
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt active IP Right Grant
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
-
2025
- 2025-05-06 US US19/200,356 patent/US20260070897A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020000360A1 (es) | 2020-07-31 |
| AU2018317403A1 (en) | 2020-03-12 |
| CN111225913B (zh) | 2024-05-31 |
| CO2020002576A2 (es) | 2020-04-01 |
| JP2020531454A (ja) | 2020-11-05 |
| EP3668865A1 (en) | 2020-06-24 |
| US11427573B2 (en) | 2022-08-30 |
| ZA202001321B (en) | 2023-10-25 |
| UA128084C2 (uk) | 2024-04-03 |
| BR112020003292A2 (pt) | 2020-08-18 |
| SG11202001264UA (en) | 2020-03-30 |
| WO2019036534A1 (en) | 2019-02-21 |
| US20200291019A1 (en) | 2020-09-17 |
| CN111225913A (zh) | 2020-06-02 |
| EA202090467A1 (ru) | 2020-06-18 |
| KR20200054204A (ko) | 2020-05-19 |
| US20190055225A1 (en) | 2019-02-21 |
| US12291521B2 (en) | 2025-05-06 |
| IL272575A (en) | 2020-03-31 |
| IL272575B1 (en) | 2023-05-01 |
| US20220259190A1 (en) | 2022-08-18 |
| US20260070897A1 (en) | 2026-03-12 |
| US10508105B2 (en) | 2019-12-17 |
| CA3072493A1 (en) | 2019-02-21 |
| KR102687118B1 (ko) | 2024-07-19 |
| JP7253832B2 (ja) | 2023-04-07 |
| IL272575B2 (en) | 2023-09-01 |
| AU2018317403B2 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200756A1 (es) | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| CL2020001343A1 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| PE20221910A1 (es) | Derivados de pirazolilo utiles como agentes anticancerigenos | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
| EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
| CO2019000686A2 (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
| EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
| PE20190503A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| EA200801934A1 (ru) | 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2 | |
| AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| JP2016513130A5 (https=) | ||
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| AR091490A1 (es) | Antagonistas de iap | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| PE20211447A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas | |
| MX360667B (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). |